2. Signaling Pathways
  3. Cytoskeleton
  4. Tissue Factor Pathway Inhibitor (TFPI)
  5. Tissue Factor Pathway Inhibitor (TFPI) Inhibitor

Tissue Factor Pathway Inhibitor (TFPI) Inhibitor

Tissue Factor Pathway Inhibitor (TFPI) Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-P99725
    Marstacimab
    		Inhibitor
    Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
  • HY-153480A
    ARC19499 sodium
    		Inhibitor
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
  • HY-P99465
    Befovacimab
    		Inhibitor ≥99.0%
    Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research.
  • HY-153480
    ARC19499
    		Inhibitor
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
  • HY-P991379
    MG1113A
    		Inhibitor
    MG1113A is a human monoclonal antibody (mAb) targeting TFPI. MG1113A can be used in Haemophilia research.